Hospitalizations for invasive pneumococcal disease among human immunodeficiency virus-1 infected children, adolescents and young adults in the United States in the era of highly active antiretroviral therapy and the conjugate pneumococcal vaccine

Pediatr Infect Dis J. 2010 Jun;29(6):561-3. doi: 10.1097/INF.0b013e3181cfb65f.

Abstract

We describe hospitalization trends of invasive pneumococcal disease (IPD) among human immunodeficiency virus-infected individuals <25 years of age since the introduction of highly active antiretroviral therapy (HAART) and the 7-valent pneumococcal conjugate vaccine (PCV7) in the United States, using the Nationwide Inpatient Sample. We estimated national trends of IPD hospitalizations during 3 periods: 1994 to 1995 (pre-HAART and pre-PCV7 era); 1998 to 1999 (HAART and pre-PCV7 era); and 2004 to 2005 (HAART and early PCV7 era). The number of IPD hospitalizations among human immunodeficiency virus-infected children and youth <25 years in the United States declined by 78.7% between 1994/1995 and 2004/2005 (P = 0.03). This decrease was more pronounced among younger children.

MeSH terms

  • Adolescent
  • Antiretroviral Therapy, Highly Active*
  • Child
  • Child, Preschool
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology
  • HIV Infections / microbiology*
  • HIV-1
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Hospitalization / statistics & numerical data
  • Humans
  • Infant
  • Male
  • Odds Ratio
  • Pneumococcal Infections / epidemiology
  • Pneumococcal Infections / virology*
  • Pneumococcal Vaccines / administration & dosage*
  • United States / epidemiology
  • Young Adult

Substances

  • Heptavalent Pneumococcal Conjugate Vaccine
  • Pneumococcal Vaccines